S&P 500   3,819.83 (-1.30%)
DOW   31,272.44 (-0.38%)
QQQ   310.67 (-2.43%)
AAPL   122.84 (-1.82%)
MSFT   228.02 (-2.50%)
FB   257.01 (-0.77%)
GOOGL   2,026.47 (-1.84%)
TSLA   656.41 (-4.37%)
AMZN   3,020.49 (-2.39%)
NVDA   516.02 (-3.77%)
BABA   236.24 (+0.78%)
CGC   33.45 (-5.11%)
GE   13.52 (+4.16%)
MU   90.21 (-0.97%)
NIO   41.23 (-4.76%)
AMD   81.66 (-2.94%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   525.01 (-4.16%)
PFE   34.34 (+2.48%)
S&P 500   3,819.83 (-1.30%)
DOW   31,272.44 (-0.38%)
QQQ   310.67 (-2.43%)
AAPL   122.84 (-1.82%)
MSFT   228.02 (-2.50%)
FB   257.01 (-0.77%)
GOOGL   2,026.47 (-1.84%)
TSLA   656.41 (-4.37%)
AMZN   3,020.49 (-2.39%)
NVDA   516.02 (-3.77%)
BABA   236.24 (+0.78%)
CGC   33.45 (-5.11%)
GE   13.52 (+4.16%)
MU   90.21 (-0.97%)
NIO   41.23 (-4.76%)
AMD   81.66 (-2.94%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   525.01 (-4.16%)
PFE   34.34 (+2.48%)
S&P 500   3,819.83 (-1.30%)
DOW   31,272.44 (-0.38%)
QQQ   310.67 (-2.43%)
AAPL   122.84 (-1.82%)
MSFT   228.02 (-2.50%)
FB   257.01 (-0.77%)
GOOGL   2,026.47 (-1.84%)
TSLA   656.41 (-4.37%)
AMZN   3,020.49 (-2.39%)
NVDA   516.02 (-3.77%)
BABA   236.24 (+0.78%)
CGC   33.45 (-5.11%)
GE   13.52 (+4.16%)
MU   90.21 (-0.97%)
NIO   41.23 (-4.76%)
AMD   81.66 (-2.94%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   525.01 (-4.16%)
PFE   34.34 (+2.48%)
S&P 500   3,819.83 (-1.30%)
DOW   31,272.44 (-0.38%)
QQQ   310.67 (-2.43%)
AAPL   122.84 (-1.82%)
MSFT   228.02 (-2.50%)
FB   257.01 (-0.77%)
GOOGL   2,026.47 (-1.84%)
TSLA   656.41 (-4.37%)
AMZN   3,020.49 (-2.39%)
NVDA   516.02 (-3.77%)
BABA   236.24 (+0.78%)
CGC   33.45 (-5.11%)
GE   13.52 (+4.16%)
MU   90.21 (-0.97%)
NIO   41.23 (-4.76%)
AMD   81.66 (-2.94%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   525.01 (-4.16%)
PFE   34.34 (+2.48%)
Log in
NASDAQ:ESPR

Esperion Therapeutics Competitors

$27.83
+0.07 (+0.25 %)
(As of 03/3/2021 03:43 PM ET)
Add
Compare
Today's Range
$27.43
Now: $27.83
$28.34
50-Day Range
$25.12
MA: $29.66
$36.89
52-Week Range
$23.90
Now: $27.83
$56.85
Volume21,407 shs
Average Volume965,214 shs
Market Capitalization$777.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48

Competitors

Esperion Therapeutics (NASDAQ:ESPR) Vs. PCRX, OPK, ALXO, ALKS, RCKT, and FOLD

Should you be buying ESPR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Esperion Therapeutics, including Pacira BioSciences (PCRX), OPKO Health (OPK), ALX Oncology (ALXO), Alkermes (ALKS), Rocket Pharmaceuticals (RCKT), and Amicus Therapeutics (FOLD).

Esperion Therapeutics (NASDAQ:ESPR) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk & Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and Pacira BioSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics23312.33
Pacira BioSciences04702.64

Esperion Therapeutics presently has a consensus target price of $52.8889, indicating a potential upside of 87.88%. Pacira BioSciences has a consensus target price of $76.0909, indicating a potential upside of 9.11%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Pacira BioSciences.

Valuation and Earnings

This table compares Esperion Therapeutics and Pacira BioSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.19$-97,170,000.00($3.59)-7.67
Pacira BioSciences$421.03 million7.17$-11,020,000.00$0.8680.81

Pacira BioSciences has higher revenue and earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and Pacira BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
Pacira BioSciences29.95%10.71%4.88%

Summary

Pacira BioSciences beats Esperion Therapeutics on 10 of the 13 factors compared between the two stocks.

Esperion Therapeutics (NASDAQ:ESPR) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk and Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Insider & Institutional Ownership

28.5% of OPKO Health shares are held by institutional investors. 7.7% of Esperion Therapeutics shares are held by company insiders. Comparatively, 40.9% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and OPKO Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics23312.33
OPKO Health00203.00

Esperion Therapeutics presently has a consensus target price of $52.8889, indicating a potential upside of 87.88%. OPKO Health has a consensus target price of $9.00, indicating a potential upside of 103.62%. Given OPKO Health's stronger consensus rating and higher possible upside, analysts plainly believe OPKO Health is more favorable than Esperion Therapeutics.

Valuation and Earnings

This table compares Esperion Therapeutics and OPKO Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.19$-97,170,000.00($3.59)-7.67
OPKO Health$901.90 million3.24$-314,920,000.00($0.41)-10.63

Esperion Therapeutics has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and OPKO Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
OPKO Health-9.79%-2.61%-1.80%

Summary

OPKO Health beats Esperion Therapeutics on 10 of the 15 factors compared between the two stocks.

Esperion Therapeutics (NASDAQ:ESPR) and ALX Oncology (NASDAQ:ALXO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Insider & Institutional Ownership

73.5% of ALX Oncology shares are held by institutional investors. 7.7% of Esperion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and ALX Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics23312.33
ALX Oncology00603.00

Esperion Therapeutics presently has a consensus target price of $52.8889, indicating a potential upside of 87.88%. ALX Oncology has a consensus target price of $89.60, indicating a potential upside of 6.63%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than ALX Oncology.

Valuation and Earnings

This table compares Esperion Therapeutics and ALX Oncology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.19$-97,170,000.00($3.59)-7.67
ALX OncologyN/AN/AN/AN/AN/A

ALX Oncology has lower revenue, but higher earnings than Esperion Therapeutics.

Profitability

This table compares Esperion Therapeutics and ALX Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
ALX OncologyN/AN/AN/A

Summary

ALX Oncology beats Esperion Therapeutics on 6 of the 10 factors compared between the two stocks.

Esperion Therapeutics (NASDAQ:ESPR) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk and Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Insider & Institutional Ownership

97.3% of Alkermes shares are held by institutional investors. 7.7% of Esperion Therapeutics shares are held by company insiders. Comparatively, 4.5% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and Alkermes, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics23312.33
Alkermes17102.00

Esperion Therapeutics presently has a consensus target price of $52.8889, indicating a potential upside of 87.88%. Alkermes has a consensus target price of $20.25, indicating a potential upside of 7.77%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Alkermes.

Valuation and Earnings

This table compares Esperion Therapeutics and Alkermes' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.19$-97,170,000.00($3.59)-7.67
Alkermes$1.17 billion2.53$-196,620,000.00$0.07266.00

Esperion Therapeutics has higher earnings, but lower revenue than Alkermes. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and Alkermes' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
Alkermes-6.28%9.35%5.50%

Summary

Esperion Therapeutics beats Alkermes on 9 of the 15 factors compared between the two stocks.

Esperion Therapeutics (NASDAQ:ESPR) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Risk & Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and Rocket Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics23312.33
Rocket Pharmaceuticals011302.93

Esperion Therapeutics presently has a consensus target price of $52.8889, indicating a potential upside of 87.88%. Rocket Pharmaceuticals has a consensus target price of $58.50, indicating a potential upside of 7.52%. Given Esperion Therapeutics' higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Rocket Pharmaceuticals.

Valuation and Earnings

This table compares Esperion Therapeutics and Rocket Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.19$-97,170,000.00($3.59)-7.67
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-33.46

Rocket Pharmaceuticals has lower revenue, but higher earnings than Esperion Therapeutics. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and Rocket Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
Rocket PharmaceuticalsN/A-35.81%-27.52%

Summary

Rocket Pharmaceuticals beats Esperion Therapeutics on 8 of the 12 factors compared between the two stocks.

Esperion Therapeutics (NASDAQ:ESPR) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Risk and Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Valuation & Earnings

This table compares Esperion Therapeutics and Amicus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.19$-97,170,000.00($3.59)-7.67
Amicus Therapeutics$182.24 million15.26$-356,390,000.00($1.31)-8.15

Esperion Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Esperion Therapeutics and Amicus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
Amicus Therapeutics-120.18%-73.81%-36.10%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Esperion Therapeutics and Amicus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics23312.33
Amicus Therapeutics08502.38

Esperion Therapeutics presently has a consensus target price of $52.8889, indicating a potential upside of 87.88%. Amicus Therapeutics has a consensus target price of $20.1923, indicating a potential upside of 83.57%. Given Esperion Therapeutics' higher possible upside, equities research analysts clearly believe Esperion Therapeutics is more favorable than Amicus Therapeutics.

Summary

Amicus Therapeutics beats Esperion Therapeutics on 8 of the 13 factors compared between the two stocks.


Esperion Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$69.50-2.7%$3.10 billion$421.03 million24.47Earnings Announcement
Analyst Report
News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$4.36-6.0%$3.10 billion$901.90 million-24.22
ALX Oncology logo
ALXO
ALX Oncology
1.9$83.17-0.2%$3.09 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Alkermes logo
ALKS
Alkermes
1.2$18.62-3.1%$3.06 billion$1.17 billion-40.48Analyst Revision
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$52.87-3.9%$3.03 billionN/A-29.05Earnings Announcement
Analyst Report
Analyst Revision
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.67-4.7%$2.91 billion$182.24 million-9.28Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.44-1.4%$2.91 billion$306.49 million27.46
Viela Bio logo
VIE
Viela Bio
0.8$52.99-0.1%$2.91 billion$50 million-7.55Earnings Announcement
Decrease in Short Interest
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$33.08-4.1%$2.79 billion$60,000.00-10.27Earnings Announcement
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.50-0.7%$2.75 billion$644.77 million-10.34Increase in Short Interest
IGMS
IGM Biosciences
1.7$80.23-11.3%$2.74 billionN/A-34.14
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$42.55-3.5%$2.74 billion$2.11 million-9.21Analyst Revision
PRLD
Prelude Therapeutics
1.0$58.39-7.1%$2.73 billionN/A0.00Upcoming Earnings
Xencor logo
XNCR
Xencor
1.0$44.40-3.7%$2.67 billion$156.70 million-31.71Analyst Upgrade
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.6$70.09-0.5%$2.61 billionN/A-26.06Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$34.69-4.6%$2.57 billion$15 million-18.16Analyst Report
Analyst Revision
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.42-0.2%$2.55 billion$25 million-8.88
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.86-4.1%$2.54 billion$120.28 million-148.34Decrease in Short Interest
Amarin logo
AMRN
Amarin
1.6$5.83-3.4%$2.34 billion$429.76 million-116.58Earnings Announcement
Cryoport logo
CYRX
Cryoport
1.7$54.13-9.0%$2.34 billion$33.94 million-93.33Earnings Announcement
Analyst Upgrade
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$28.28-4.3%$2.21 billion$23.90 million-17.57Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
MORF
Morphic
1.1$69.76-1.9%$2.21 billion$16.98 million-44.72Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$22.87-6.0%$2.20 billionN/A-8.14
Generation Bio logo
GBIO
Generation Bio
1.4$40.35-5.1%$2.13 billionN/A0.00Upcoming Earnings
Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.41-0.9%$2.09 billion$963.01 million13.17
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$57.43-4.1%$2.09 billionN/A0.00Upcoming Earnings
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$59.11-1.5%$2.01 billionN/A-32.84
HRMY
Harmony Biosciences
1.2$34.65-0.7%$1.99 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Kura Oncology logo
KURA
Kura Oncology
1.6$29.36-2.1%$1.99 billionN/A-18.01Earnings Announcement
Analyst Report
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$28.20-3.3%$1.88 billion$103.54 million-21.20Insider Selling
ADCT
ADC Therapeutics
1.6$25.89-4.6%$1.87 billion$2.34 million-10.97Upcoming Earnings
News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.24-1.3%$1.84 billion$320,000.00-9.69Analyst Revision
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.1$61.46-0.4%$1.81 billion$970,000.000.00Upcoming Earnings
Increase in Short Interest
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$17.18-14.2%$1.79 billion$34.51 million-14.68Earnings Announcement
Analyst Report
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.02-2.1%$1.77 billionN/A-10.12Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$44.26-1.7%$1.77 billionN/A0.00Upcoming Earnings
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.73-3.9%$1.77 billion$82.27 million-21.29
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$32.43-8.0%$1.75 billionN/A-3.51
Shattuck Labs logo
STTK
Shattuck Labs
1.3$40.09-4.1%$1.74 billionN/A0.00Upcoming Earnings
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$25.55-2.0%$1.73 billion$410,000.00-5.55Analyst Report
ORGO
Organogenesis
1.0$15.17-5.5%$1.73 billion$260.98 million-252.83
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$45.38-5.4%$1.72 billionN/A0.00Upcoming Earnings
News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$34.41-6.4%$1.69 billion$29.54 million-9.13Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
Endo International logo
ENDP
Endo International
1.1$6.89-4.9%$1.67 billion$2.91 billion-10.13Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.8$29.30-0.2%$1.64 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.57-0.6%$1.62 billion$145.97 million-7.11Earnings Announcement
Analyst Revision
uniQure logo
QURE
uniQure
1.9$35.20-2.2%$1.60 billion$7.28 million-9.34Earnings Announcement
Analyst Report
Analyst Revision
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$44.95-5.0%$1.59 billion$28.95 million-64.21Insider Selling
Gap Down
NKTX
Nkarta
1.6$46.27-4.9%$1.58 billionN/A0.00Upcoming Earnings
ATBPD
Antibe Therapeutics
0.1$4.06-3.4%$1.57 billion$7.51 million-6.77
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.